Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36922
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Opat S. | en |
dc.contributor.author | Casan J.M.L. | en |
dc.contributor.author | Wong J. | en |
dc.contributor.author | Northcott M.J. | en |
dc.date.accessioned | 2021-05-14T12:32:27Z | en |
dc.date.available | 2021-05-14T12:32:27Z | en |
dc.date.copyright | 2018 | en |
dc.date.created | 20190622 | en |
dc.date.issued | 2019-06-22 | en |
dc.identifier.citation | Human Vaccines and Immunotherapeutics. 14 (12) (pp 2820-2841), 2018. Date of Publication: 02 Dec 2018. | en |
dc.identifier.issn | 2164-5515 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/36922 | en |
dc.description.abstract | Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.Copyright © 2018, © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Taylor and Francis Inc. (325 Chestnut St, Suite 800, Philadelphia PA 19106, United States) | en |
dc.relation.ispartof | Human Vaccines and Immunotherapeutics | en |
dc.title | Anti-CD20 monoclonal antibodies: reviewing a revolution. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/21645515.2018.1508624 | en |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 30096012 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30096012] | en |
dc.identifier.source | 628015752 | en |
dc.identifier.institution | (Casan, Wong, Opat) Haematology Department, Monash Health, Melbourne, Australia (Northcott) Rheumatology Department, Monash Health, Melbourne, Australia (Northcott, Opat) School of Clinical Sciences, Monash University, Melbourne, Australia | en |
dc.description.address | J.M.L. Casan, Monash Haematology, level 4, 246 Clayton Rd, Clayton, VIC 3168, Australia. E-mail: joshua.casan@gmail.com | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | CD20 immunotherapy lymphoma Monoclonal antibody obinutuzumab rituximab | en |
dc.identifier.authoremail | Casan J.M.L.; joshua.casan@gmail.com | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.